Tag: Priovant Therapeutics
-
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.